Autres langues BioPorto A/S

Actions

Marché Fermé - Nasdaq Copenhagen Autres places de cotation 16:59:46 08/05/2024			Varia. 5j.	Varia. 1 janv.
1,628 ^DKK	+11,35%		+25,04%	-22,11%

08/05	BioPorto A/S publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI
08/05	Bioporto A/S donne des prévisions de recettes pour 2024	CI

First Quarter 2024: Strong growth in US sales of The NGAL Test	08/05
BioPorto A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Bioporto A/S Provides Revenue Guidance for 2024	08/05
Resolutions of Annual Geneal Meeting	30/04
Grant of warrants	23/04
BioPorto Names New Chief Legal Officer	10/04
BioPorto A/S Appoints Chief Legal Officer	10/04
Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024	10/04
New Board Candidate for the upcoming Annual Geneal Meeting	05/04
Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election	05/04
Notice convening the Annual General Meeting in BioPorto A/S	04/04
Correction: BioPorto Announces Annual Results for 2023	04/04
BioPorto Announces Annual Results for 2023	04/04
BioPorto A/S Reports Earnings Results for the Full Year Ended December 31, 2023	04/04
BioPorto Makes Interim CEO Permanent	02/04
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer	02/04
BioPorto A/S Appoints Peter Mørch Eriksen as Permanent Group CEO	02/04
Bioporto A/S Announces Peter Mørch Eriksen Will Not Stand for Re-Election to the Board of Directors	02/04
BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026	22/02
BioPorto A/S Provides Revenue Guidance for the Full Year 2024	22/02

Aucun résultat pour cette recherche